SMMT Share Price | Summit Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Summit Therapeutics, Inc.?

Market Cap: As of Jun 18, Summit Therapeutics, Inc. has a market capitalization of 14,741.92 million, classifying it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -240.75 million.Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 388.75 million, while total assets were reported at 435.56 million.

Q: What does Summit Therapeutics, Inc. do?

Overview: Summit Therapeutics, Inc. is focused on developing treatments for infectious diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Market cap: USD 14,741.92 Million (Small Cap) Net Profit: -63 Million (Quarterly Results - Mar 2025)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.04 Return on Equity: -65.56% Price to Book: 42.81Contact Details: Address: One Broadway, 14Th Floor, CAMBRIDGE MA: 02142 Tel: 1 617 5147149 Fax: 1 302 6555049

Q: Is Summit Therapeutics, Inc. overvalued or undervalued?

As of 9 November 2022, the valuation grade for Summit Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, with a Price to Book Value ratio of 44.41 and an EV to EBIT of -63.40, reflecting its loss-making status. Additionally, the Return on Equity (ROE) stands at a concerning -65.56%, which further underscores the challenges the company faces.In comparison to its peers, Summit Therapeutics, Inc. shows a stark contrast; for instance, Merus NV has a P/E ratio of -14.25 and an EV to EBITDA of -11.71, while Rhythm Pharmaceuticals, Inc. has a P/E of -22.45 and an EV to EBITDA of -22.69. These ratios highlight that Summit is not only underperforming relative to its peers but also lacks a viable valuation framework. Despite recent strong stock performance against the S&P 500, with a 1-year return of 157.12% compared to the index's 10.26%, the underlying financial metrics suggest that the stock is not justified at its current price level.

Q: Is Summit Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Summit Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD is bearish and the monthly MACD is mildly bearish. The Bollinger Bands show a mixed signal with the weekly being mildly bearish and the monthly bullish. Overall, the Dow Theory suggests a mildly bullish trend on the weekly timeframe, but no trend on the monthly.In terms of performance, the stock has outperformed the S&P 500 on a weekly basis with a return of 4.68% compared to 1.09%, but it has underperformed over the past month with a return of -14.74% against the S&P 500's 4.15%. Year-to-date, the stock shows a strong return of 24.12%, exceeding the S&P 500's 14.18%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.69 M

Shareholding (Dec 2025)

FII

2.57%

Held by 133 FIIs

DII

90.13%

Held by 21 DIIs

Promoter

0.10%

How big is Summit Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Summit Therapeutics, Inc. has a market capitalization of 14,741.92 million, classifying it as a Small Cap company, with net sales of 0.00 million and a net profit of -240.75 million for the latest four quarters. As of December 2024, shareholder's funds were 388.75 million and total assets were 435.56 million.

View full answer

What does Summit Therapeutics, Inc. do?

22-Jun-2025

Summit Therapeutics, Inc. develops treatments for infectious diseases in the Pharmaceuticals & Biotechnology sector. It has a market cap of approximately $14.74 billion and reported a net profit loss of $63 million as of March 2025.

View full answer

Who are in the management team of Summit Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Summit Therapeutics, Inc. includes Dr. Elaine Stracker as Executive Director and Mr. Rainer Erdtmann as Non-Executive Independent Director.

View full answer

Is Summit Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 9, 2022, Summit Therapeutics, Inc. is overvalued with a valuation grade of "does not qualify," reflecting significant financial deterioration, highlighted by a Price to Book Value ratio of 44.41, an EV to EBIT of -63.40, and a concerning -65.56% Return on Equity, despite a strong stock performance of 157.12% over the past year compared to the S&P 500's 10.26%.

View full answer

Is Summit Therapeutics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Summit Therapeutics, Inc. shows a mildly bullish trend driven by daily moving averages, despite mixed signals from MACD and Bollinger Bands, with a year-to-date return of 24.12% outperforming the S&P 500's 14.18%.

View full answer

Compare Summit Therapeutics, Inc. with Similar Stocks

Rhythm Pharmaceuticals, Inc.Merus NV Maravai Lifesciences Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 12,542 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.23

Return on Equity

-479.35%

Price to Book

65.23

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-219 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.39%

6 Months

-11.45%

1 Year

-11.36%

2 Years

446.95%

3 Years

919.32%

4 Years

531.69%

5 Years

226.78%

Summit Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-263.08%

EBIT to Interest (avg)

-47.20

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.04%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.18%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

65.23

EV to EBIT

-13.16

EV to EBITDA

-13.16

EV to Capital Employed

-280.36

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-479.35%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 52 Schemes (7.2%)

Foreign Institutions

Held by 133 Foreign Institutions (2.57%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 5.44% vs 59.02% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-224.90",
          "val2": "-234.20",
          "chgp": "3.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-219.20",
          "val2": "-231.80",
          "chgp": "5.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -387.84% vs 64.01% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1,094.30",
          "val2": "-211.20",
          "chgp": "-418.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "8.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-15.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,079.60",
          "val2": "-221.30",
          "chgp": "-387.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-224.90

-234.20

3.97%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-219.20

-231.80

5.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 5.44% vs 59.02% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1,094.30

-211.20

-418.13%

Interest

0.00

8.70

-100.00%

Exceptional Items

0.00

-15.00

100.00%

Consolidate Net Profit

-1,079.60

-221.30

-387.84%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -387.84% vs 64.01% in Dec 2024

All Annual Results

Company CV

About Summit Therapeutics, Inc.

Summit Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Summit Therapeutics Inc. is focused on developing treatments for infectious diseases. The Company uses its Discuva platform, an antibiotic discovery engine to develop antibiotics. It is initially focused on Clostridioides difficile infections (CDI). Its platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. Ridinilazole is its new mechanism antibiotic, which is being developed for CDI.

Company Coordinates

Company Details

One Broadway, 14Th Floor , CAMBRIDGE MA : 02142

Tel: 1 617 5147149

Registrar Details